Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.25
Bid: 15.00
Ask: 15.50
Change: -0.25 (-1.61%)
Spread: 0.50 (3.333%)
Open: 15.00
High: 15.50
Low: 14.65
Prev. Close: 15.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commercial Sale

31 Jan 2007 07:02

Angle PLC31 January 2007 For Immediate Release 31 January 2007 ANGLE plc ('ANGLE' or 'the Company') First Commercial Sale of Synature Product ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce that its Progeny(R)venture company Synature, which offers a new and innovative approach to onlinemarketing, has secured its first commercial sale with a leading player in theworld's most active markets for package holidays and other leisure travelservices. Together they have launched Holiday Matchmaker, a new way for holidaybuyers to find their ideal destination based on recommendations from like-mindedpeople. This is the first commercial sale of Synature's unique patentedtechnology qubox(TM). Holiday Matchmaker utilises Synature's "attitudinal matching" approach todevelop principles derived from constructivist psychology to measure a person'sfeelings on a particular subject - in this case holidays - and thereby connectweb users to relevant content. Feelings are measured in a fun, engaging wayusing Synature's unique proprietary technology qubox(TM), to complete an online'questionnaire'. The results are then processed with state-of-the-art patternrecognition algorithms, derived from research at the University of Cambridge,UK, to provide personalised recommendations. Thousands of users of the customer's website have taken part in a surveyspecifically designed for the launch of the Holiday Matchmaker, which providesrecommendations based entirely on the opinions of an "online jury". The recommendation system uses a scientific measure of like-mindedness to ensurea client's holiday suggestions come from people with compatible views. Thesystem provides suggestions in multiple categories, including "essential picks","dream holidays" and "quirky choices". John Woods, Chief Executive of Synature, commented: "The Holiday Matchmaker is a new way of searching for a travel product. Itsresults are based on the unbiased opinions of a like-minded peer group. Whereasprevious generations of search and personalisation technology have struggledwith complex products such as travel, our approach built on like-mindedness andusing the power of the social internet takes this product complexity in itsstride. We can even tackle hypothetical questions, such as the idea ofrecommending a 'dream holiday'." Andrew Newland, Chief Executive of ANGLE plc, added: "We are delighted that Synature has secured its first commercial sale with aleading player in the holiday market. The Synature qubox(TM)technology has wideapplication in many online markets and we look forward to further developments." For further information ANGLE plc +44 (0)1483 295830Andrew Newland, Chief Executive Synature +44 (0)8701 909550John Woods, Chief Executive Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors: About Synature Synature (www.synature.com) was created by ANGLE in early 2005 to commercialiseintellectual property developed by a Cambridge-based team which offers a newapproach to online target marketing. The company has developed this"attitudinal matching" approach into an ASP service offering advanced socialsearch functionality usable by all types of website including e-commerce, socialnetworks, portals and content sites. About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from offices inthe UK, the US and the Middle East. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.